Trulicity and Rosuvastatin Interaction: What Patients and Clinicians Need to Know

Do Trulicity and Rosuvastatin Interact?

Trulicity (dulaglutide) and rosuvastatin do not share a clinically significant pharmacokinetic interaction that would require dose modification or contraindicate co-administration. The two drugs travel distinct metabolic routes: dulaglutide is degraded by general protein catabolism pathways, not cytochrome P450 enzymes, while rosuvastatin relies primarily on OATP1B1, OATP1B3, and BCRP transporters for hepatic uptake and efflux. [1] [2]

The practical outcome is that combining these two drugs in a patient with type 2 diabetes and dyslipidemia is common, well-tolerated, and supported by cardiovascular outcome data from both drug classes.

What the FDA Labels Actually Say

The dulaglutide prescribing information does not list rosuvastatin as an interacting drug. [1] The rosuvastatin label does identify several transporter-based interactions, including gemfibrozil (which roughly doubles rosuvastatin AUC) and cyclosporine, but does not name GLP-1 receptor agonists as interaction partners. [2] This absence is meaningful: the label interactions were informed by dedicated in vivo drug-drug interaction studies during clinical development.

Why Gastric Emptying Still Deserves Attention

Dulaglutide slows gastric emptying through GLP-1 receptor activation on enteric neurons. A crossover pharmacokinetic study of liraglutide (a closely related GLP-1 agonist) and oral medications found that gastric slowing delayed Tmax for some co-administered drugs by 30 to 90 minutes without meaningfully changing AUC. [3] Rosuvastatin is absorbed in the small intestine, so a delay in gastric transit could shift the timing of peak plasma concentrations. The clinical implication is subtle: rosuvastatin is already recommended to be taken consistently at the same time of day, so Tmax shifting by an hour does not alter its steady-state LDL-lowering effect.

Mechanism Deep-Dive: Pharmacokinetics of Each Drug

Understanding why this interaction is low-risk requires looking at how each molecule is handled by the body.

Dulaglutide Pharmacokinetics

Dulaglutide is a large-molecule GLP-1 receptor agonist fused to a modified IgG4 Fc fragment, giving it a half-life of approximately 5 days and allowing once-weekly subcutaneous dosing. [1] It is not metabolized by CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4. It is not a substrate or inhibitor of P-glycoprotein or BCRP. It does not bind to plasma proteins in a way that displaces co-administered drugs. General proteolytic catabolism accounts for its elimination. [1]

This pharmacokinetic profile means dulaglutide has virtually no potential to alter the plasma concentrations of drugs whose clearance depends on CYP enzymes or ABC transporters.

Rosuvastatin Pharmacokinetics

Rosuvastatin is a hydrophilic statin that undergoes minimal CYP2C9-mediated metabolism (roughly 10% of the absorbed dose). [2] Its primary route into hepatocytes, the site of its pharmacological action, depends on OATP1B1 and OATP1B3 transporters encoded by the SLCO1B1 and SLCO1B3 genes. Efflux from the intestinal epithelium into the portal circulation involves BCRP (ABCG2). [4] Genetic variants in SLCO1B1 (particularly the c.521T>C variant, also called SLCO1B1*5) reduce OATP1B1 function and raise rosuvastatin plasma exposure, increasing myopathy risk independently of any co-administered drug. [5]

Oral bioavailability is approximately 20%, peak plasma concentrations occur at 3 to 5 hours after dosing, and approximately 90% of an absorbed dose is excreted in feces via biliary elimination. [2] Renal excretion accounts for about 28% of total body clearance. [2]

Because dulaglutide does not interact with OATP1B1, OATP1B3, or BCRP, it cannot raise rosuvastatin systemic exposure through transporter inhibition.

Where the Two Pathways Touch

The only mechanistic overlap is the gastric-emptying effect described above. Slowing gastric transit delays entry of oral rosuvastatin into the small intestine, which may extend the time to Cmax. A 2011 pharmacokinetic analysis of exenatide (another GLP-1 agonist) co-administered with lovastatin showed a 28% reduction in lovastatin Cmax but no change in AUC. [6] Lovastatin and rosuvastatin are structurally different, but this study illustrates the category effect: peak plasma concentration of an oral statin may fall modestly while total drug exposure is preserved.

Clinical Severity Classification

Drug-drug interaction databases classify this combination differently depending on the platform consulted.

Lexicomp and Micromedex Ratings

Lexicomp categorizes the dulaglutide-rosuvastatin interaction as a Category C interaction, meaning monitoring is recommended but the combination is not contraindicated. [7] Micromedex assigns a similar "moderate" designation based on the theoretical gastric-emptying mechanism, not on documented adverse outcome data from clinical trials. [7]

These ratings reflect prudent caution about a pharmacokinetic effect that is real in principle but small in practice. Neither database cites case reports of harm specific to this combination.

Cardiovascular Outcome Trials: Both Drugs Deliver Benefit

The REWIND trial (N=9,901) studied dulaglutide 1.5 mg weekly versus placebo in patients with type 2 diabetes and found a 12% relative risk reduction in major adverse cardiovascular events (MACE) over a median follow-up of 5.4 years (HR 0.88, 95% CI 0.79-0.99). [8] The majority of REWIND participants were on background statin therapy, making this one of the largest real-world datasets showing dulaglutide and statins co-administered safely.

The JUPITER trial (N=17,802) demonstrated that rosuvastatin 20 mg reduced MACE by 44% in patients with elevated hsCRP and normal LDL. [9] Patients with metabolic syndrome, many of whom would now be candidates for GLP-1 therapy, comprised a substantial proportion of that cohort.

The co-prescription of a GLP-1 receptor agonist and a statin is therefore not only safe but arguably the standard of care for patients with type 2 diabetes and atherosclerotic cardiovascular disease or high cardiovascular risk.

Myopathy Risk: Statin-Class Effect, Not an Interaction

Rosuvastatin carries a class-wide risk of skeletal muscle toxicity. The incidence of clinically significant myopathy (defined as muscle symptoms with CK > 10 times the upper limit of normal) is roughly 0.1% at doses of 10 to 20 mg and increases with higher doses, especially rosuvastatin 40 mg. [2] [10]

Dulaglutide does not share any pharmacological mechanism that would amplify this risk. It does not inhibit mitochondrial fatty acid oxidation, does not deplete CoQ10 in muscle, and has no receptor expression in skeletal muscle relevant to toxicity. [1] The risk factors for rosuvastatin-induced myopathy are well-characterized and include:

• Rosuvastatin dose of 40 mg daily
• SLCO1B1*5 genetic variant (discussed above)
• Hypothyroidism
• Co-administration of gemfibrozil, cyclosporine, or certain antifungals
• Renal impairment (CrCl <30 mL/min raises rosuvastatin exposure significantly)
• Age over 65 and low body mass

None of these risk factors involves GLP-1 receptor agonist use. [10]

When to Check Creatine Kinase

Baseline CK measurement before starting rosuvastatin is not required for most patients by current AHA/ACC guidelines, but is reasonable if the patient reports pre-existing muscle symptoms or has multiple myopathy risk factors. [11] If a patient on dulaglutide plus rosuvastatin reports new muscle pain, weakness, or brown urine, a CK level and basic metabolic panel should be obtained promptly. Rhabdomyolysis requires hospitalization, IV fluids, and statin discontinuation; it does not require dulaglutide discontinuation.

Drug Interaction Screening in Context: Other Rosuvastatin Interactions to Know

While dulaglutide and rosuvastatin carry low interaction risk, the clinician prescribing this combination should screen the full medication list for rosuvastatin interactions that do carry clinical weight.

High-Risk Rosuvastatin Combinations

Gemfibrozil raises rosuvastatin AUC by approximately 2-fold via OATP1B1 inhibition; the FDA label caps rosuvastatin at 10 mg daily when gemfibrozil is prescribed. [2] Cyclosporine raises rosuvastatin AUC by approximately 7-fold; the combination is contraindicated per labeling. [2] Atazanavir/ritonavir raises rosuvastatin AUC by approximately 3-fold. [2] These interactions exist entirely independent of any GLP-1 agent.

Niacin and Fibrate Combinations with Statins

The AIM-HIGH trial found no cardiovascular benefit from adding extended-release niacin to simvastatin in patients with controlled LDL, and combination niacin-statin regimens raise myopathy risk. [12] The same logic applies when a fibrate other than gemfibrozil is added: fenofibrate is preferred over gemfibrozil when a fibrate is needed alongside rosuvastatin because fenofibrate does not significantly inhibit OATP1B1.

Monitoring Protocol for Co-Prescribed Patients

The following monitoring approach applies to a patient starting dulaglutide while already on rosuvastatin, or starting rosuvastatin while already on dulaglutide.

Before Starting the Combination

• Confirm current rosuvastatin dose. Doses of 5 to 20 mg carry the lowest myopathy risk.
• Review the full medication list for known rosuvastatin OATP1B1 inhibitors (gemfibrozil, cyclosporine, certain antiretrovirals).
• Check baseline renal function. EGFR <30 mL/min/1.73m² warrants rosuvastatin dose reduction to 5 mg regardless of GLP-1 co-administration.
• Obtain baseline LDL-C, ALT, and AST. A lipid panel at baseline allows meaningful comparison at 6-week follow-up.
• Ask about muscle symptoms before adding rosuvastatin. Pre-existing myalgia should prompt discussion of an alternative statin.

At 6 to 12 Weeks

• Repeat fasting lipid panel to confirm LDL-C response to rosuvastatin.
• Review HbA1c if dulaglutide was started concurrently. The AWARD-11 trial (N=1,842) showed dulaglutide 4.5 mg weekly reduced HbA1c by a mean of 1.87 percentage points from baseline at 36 weeks. [13]
• Ask specifically about muscle pain, weakness, and dark urine at each visit.

Ongoing Surveillance

• Lipid panel annually once targets are achieved, per ACC/AHA 2019 cholesterol guidelines. [11]
• Renal function annually, since rosuvastatin dosing adjustments depend on eGFR and GLP-1 agents may modestly improve renal outcomes over time.
• CK only if muscle symptoms are reported. Routine asymptomatic CK monitoring is not recommended by the AHA. [11]

Patient Counseling Points

Patients taking both Trulicity and rosuvastatin should hear a clear, concise explanation of what to expect and what to report.

What to Tell the Patient

Rosuvastatin and Trulicity work on entirely different systems and do not cancel each other out. Rosuvastatin lowers LDL cholesterol by blocking HMG-CoA reductase in the liver. Dulaglutide lowers blood glucose and reduces cardiovascular risk through GLP-1 receptor activation. Taking both together is standard practice for patients with type 2 diabetes who are at cardiovascular risk.

The patient should report any new muscle pain, weakness, or tenderness promptly, especially if it involves the thighs, shoulders, or back. Brown or dark urine is an emergency. Nausea and vomiting from dulaglutide are expected, especially during the first four weeks of dose escalation; these symptoms do not affect rosuvastatin's cholesterol-lowering activity. [1]

Timing of Rosuvastatin Dose

Rosuvastatin can be taken at any time of day because its plasma half-life is 19 hours and its mechanism depends on hepatic accumulation over time, not on moment-to-moment plasma spikes. [2] Administering it consistently, whether morning or evening, minimizes variability. No special timing around the Trulicity injection is required.

Injection Site and Schedule Reminders

Dulaglutide is injected subcutaneously once weekly. Injection sites are the abdomen, upper arm, or thigh; the site should be rotated each week. It may be taken at any time of day, with or without food. [1] The once-weekly schedule means patients can administer it on the same day each week without coordinating with rosuvastatin dosing.

Rosuvastatin in the ADA Standards of Care: Why Most Trulicity Patients Should Be on a Statin

The American Diabetes Association 2024 Standards of Care in Diabetes recommend high-intensity statin therapy for all patients with type 2 diabetes aged 40 to 75 with atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk greater than 20% over 10 years. [14] Moderate-intensity statin therapy is recommended for patients aged 40 to 75 without other risk factors. High-intensity statins include rosuvastatin 20 to 40 mg and atorvastatin 40 to 80 mg. [14]

This guideline context means that a very large share of the patients who receive dulaglutide also meet criteria for rosuvastatin or an equivalent. Co-prescription is not an edge case. The REWIND trial finding that dulaglutide reduced MACE in a cohort where most participants were on background statin therapy provides direct reassurance that combining these therapies is not only safe but produces additive cardiovascular benefit. [8]

The ADA notes: "Most patients with type 2 diabetes should be treated with a statin to reduce cardiovascular risk regardless of baseline LDL-C level." [14]

Special Populations

Patients with Chronic Kidney Disease

Rosuvastatin exposure increases in patients with CrCl <30 mL/min/1.73m², and the FDA label recommends starting at 5 mg daily in this population. [2] Dulaglutide does not require renal dose adjustment, and observational data suggest GLP-1 receptor agonists may slow albuminuria progression in diabetic nephropathy. [15] In CKD patients on both drugs, renal function should be tracked at minimum every 6 months.

Patients with Hepatic Impairment

Rosuvastatin is contraindicated in active liver disease. [2] Dulaglutide is not hepatically cleared and does not require dose adjustment for hepatic impairment. [1] If a patient has transaminase elevations greater than 3 times the upper limit of normal, rosuvastatin should be withheld; dulaglutide can generally continue unless the elevation has a metabolic cause requiring full re-evaluation.

Older Adults Over 75

Adults over 75 are not automatically excluded from statin therapy, but the risk-benefit calculation requires individual discussion. The 2019 ACC/AHA cholesterol guideline identifies age over 75 as a factor warranting shared decision-making before initiating or escalating statins. [11] Dulaglutide is not dose-adjusted for age alone, though older adults may have lower eGFR values requiring rosuvastatin dose consideration. [1]

Patients on Cyclosporine After Transplant

Transplant patients prescribed cyclosporine should not receive rosuvastatin at doses above 5 mg regardless of co-administered GLP-1 agents, because cyclosporine is a potent OATP1B1 inhibitor that raises rosuvastatin AUC approximately 7-fold. [2] Dulaglutide is occasionally used in post-transplant diabetes and does not interact with cyclosporine through shared metabolic pathways.